OMP-131R10: Phase Ia started

OncoMed began an open-label, dose-escalation, U.S. Phase Ia/Ib trial to evaluate 5 doses of IV OMP-131R10 given on day 1 of a 14-day cycle in about 50 patients. The Phase Ia portion will enroll patien...